Summary
GHK-Cu is a copper complex of a tripeptide (a chain of three amino acids) found naturally in human plasma (the liquid part of blood), discovered in 1973 and used in cosmetics since the 1990s. Applied to the skin it has animal wound healing data and small human cosmetic studies showing improved skin elasticity, firmness, and fine lines, mostly industry associated and summarized in reviews by its discoverer. It is lawful as a cosmetic ingredient, but the injectable form sold online is an unapproved drug with no human trial; FDA lists injectable GHK-Cu as a withdrawn 503A nomination, so it is off Category 2 (FDA's list of compounding ingredients with significant safety risks) but not on the bulks list of ingredients pharmacies may use.
What is GHK-Cu?
GHK-Cu is a naturally occurring tripeptide (glycyl-histidyl-lysine) complexed with copper(II); found in human plasma, saliva, and urine. It is also known as Copper peptide, GHK copper, Glycyl-L-histidyl-L-lysine copper, Gly-His-Lys-Cu, copper tripeptide-1, Prezatide copper, GHK-Cu peptide, GHK Cu, GHKCu.
How does it work?
GHK binds copper(II) with an affinity similar to albumin's copper transport site and delivers it to cells. In cell and animal models GHK-Cu attracts macrophages, mast cells, and endothelial cells to injury sites, increases synthesis of collagen, elastin, glycosaminoglycans, and decorin, modulates matrix metalloproteinases and their inhibitors, and suppresses inflammatory signals including NF-kB and TNF-alpha. Gene expression studies suggest it shifts expression of a large number of human genes toward a repair profile. These mechanisms come from in vitro and animal work; human data are limited to skin outcomes.
| Cluster | Tissue repair and healing |
|---|---|
| Routes | Topical cream or serum (cosmetic use, the only form with human data); Subcutaneous injection (as sold; no human data); Topical, intraperitoneal, and systemic (animal studies) |
| Conditions studied | Tendon injury and tendinopathy; Skin aging and cosmetic repair; Wound healing; Hair loss (androgenetic alopecia) |
| Record | v3, draft, verified Sep 23, 2026 |
GHK-Cu benefits: topical vs injected, what studies cover
Animal studies show accelerated wound healing in rats, mice, pigs, and dogs. Human evidence consists of small controlled cosmetic studies of topical GHK-Cu creams reporting tighter skin, improved elasticity and density, fewer fine lines, and reduced photodamage, plus older reports in chronic wounds; these are summarized in reviews largely authored by the peptide's discoverer, and independent large randomized trials are lacking. The one small independent randomized trial identified (13 patients after laser resurfacing) found no objective benefit, only higher patient satisfaction; it tested a narrow use and does not raise the grade. There is no human trial of injected GHK-Cu for any indication.
| Evidence type | Indexed studies | Participants (human) |
|---|---|---|
| Human randomized trials | 1 | 13 |
| Human observational studies | 2 | n/a |
| Animal studies | 1 | n/a |
| All indexed studies | 4 | 13 |
Human evidence
Reviews report controlled studies in aged skin in which topical GHK-Cu creams tightened loose skin, improved elasticity, skin density, and firmness, reduced fine lines and wrinkles, and reduced photodamage and hyperpigmentation, and describe wound healing activity in humans. These studies are small, mostly cosmetic industry studies, and are cited through review articles rather than as independently indexed randomized trials. An independent randomized trial of GHK-Cu skin care after CO2 laser resurfacing (13 patients completed) found no difference in redness, wrinkles, or overall skin quality by blinded or computer assessment, though patients using GHK-Cu rated their skin higher. No indexed human trial of subcutaneous GHK-Cu identified.
Animal evidence
GHK-Cu accelerated healing of skin wounds, hair follicles, gastrointestinal tract, and bone in rodent and pig models, induced systemic wound healing in rats, mice, and pigs, and improved healing of foot pads in dogs. In vitro it increased fibroblast and keratinocyte proliferation, restored replicative vitality to fibroblasts after radiation, stimulated nerve outgrowth and angiogenesis, and increased hair follicle size.
Key studies
| Study | Design and population | Outcome | Grade |
|---|---|---|---|
| Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data2018 PMID 29986520 | Narrative reviewCell, animal, and human skin studies | Summarizes wound healing across skin, lung, bone, liver, and stomach in animals, and gene expression data suggesting broad regulation of repair and inflammation pathways | Evidence: Animal-only evidence |
| GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration2015 PMID 26236730 | Narrative reviewAnimal wound models and human cosmetic studies of topical GHK-Cu | Reports accelerated wound healing in rats, mice, pigs, and dogs and cosmetic study findings of tighter skin, improved elasticity and density, and fewer fine lines and wrinkles | Evidence: Human observational evidence |
| The human tri-peptide GHK and tissue remodeling2008 PMID 18644225 | Narrative reviewCell, animal, and human studies of GHK and GHK-Cu | Describes chemoattraction of repair cells, anti-inflammatory effects, increased collagen and elastin synthesis, and controlled studies in aged skin showing improved firmness and fewer wrinkles | Evidence: Human observational evidence |
| Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin2006 PMID 16847171 | Randomized trial with blinded evaluators, 12 weeksn = 13 Adults after circumoral CO2 laser resurfacing | No significant difference in redness, wrinkles, or overall skin quality by blinded or computer assessment; higher patient rated skin quality with GHK-Cu | Evidence: Human RCT evidence |
Conditions studied
| Condition | Grade | Note |
|---|---|---|
| Tendon injury and tendinopathy | Evidence: Animal-only evidence | Collagen synthesis and remodeling effects in animal and cell models; human data limited to skin. |
| Skin aging and cosmetic repair | Evidence: Human observational evidence | Small topical cosmetic studies and extensive cell data on collagen and gene expression; no injectable trials. |
| Wound healing | Evidence: Human observational evidence | Small human studies of copper peptide dressings and extensive cell and animal data. |
| Hair loss (androgenetic alopecia) | Evidence: Animal-only evidence | Reviews describe larger hair follicles and follicle cell effects in lab and animal studies; common in cosmetic serums, but no indexed human hair loss trial. |
Is GHK-Cu legal in the United States?
FDA and compounding status
GHK-Cu has two regulatory tracks. As a cosmetic ingredient in topical products it is lawfully marketed without FDA premarket approval, provided no drug claims are made. As an injectable drug it is not FDA approved and is not a component of any approved drug. GHK-Cu for injectable routes was nominated for the 503A bulks list and placed in 503A Category 2; the FDA Category 2 page current as of April 22, 2026 now lists it under bulk drug substances nominated but withdrawn, so it is no longer in Category 2 but is not on the bulks list and was not reviewed by the Pharmacy Compounding Advisory Committee in July 2026. Because it is not on the bulks list, a 503A pharmacy has no federal basis to compound injectable GHK-Cu from bulk, and state boards cannot authorize what federal law does not. Injectable products sold as research chemicals are not lawful for human use.
WADA status
WADA status unclear. The current prohibited list does not name this compound explicitly and its class status is not settled. Athletes should ask their anti-doping organization before use.
Regulatory timeline
- FDA
FDA lists BPC-157 and 16 other peptides as withdrawn from 503A Category 2
FDA's Category 2 page, revised in April 2026 and current as of April 22, 2026, moved BPC-157, AOD-9604, CJC-1295, dihexa, DSIP, epitalon, injectable GHK-Cu, ipamorelin, KPV, LL-37, melanotan II, MOTS-c, PEG-MGF, selank, semax, thymosin alpha-1, and thymosin beta-4 fragment (TB-500) to a list of bulk drug substances nominated but withdrawn by their nominators. A withdrawn substance is no longer in 503A Category 2, but withdrawal is not an approval and does not place a substance on the 503A bulks list; a 503A pharmacy still needs a listing before it may compound it. Ipamorelin acetate remains in 503B Category 2. Seven of the withdrawn peptides (BPC-157, KPV, TB-500, MOTS-c, semax, epitalon, and DSIP) were taken to the Pharmacy Compounding Advisory Committee in July 2026.
What published studies of GHK-Cu used
Ranges below are reported from published studies and labeling only. PeptideAgent does not recommend doses or protocols.
Not established in human literature for injection. Human cosmetic studies applied topical creams and serums over 8 to 12 weeks according to the reviews; no human dose finding study for injected GHK-Cu exists.
Routes reported
| # | Route |
|---|---|
| 1 | Topical cream or serum (cosmetic use, the only form with human data) |
| 2 | Subcutaneous injection (as sold; no human data) |
| 3 | Topical, intraperitoneal, and systemic (animal studies) |
GHK-Cu side effects
Side effects
| # | Reported side effect |
|---|---|
| 1 | Topical: generally well tolerated in cosmetic studies; occasional irritation or contact sensitivity |
| 2 | Injectable: no systematic human safety data |
| 3 | Injection site pain and irritation reported anecdotally |
| 4 | Theoretical copper toxicity with large repeated injected doses (not documented) |
| 5 | Theoretical concern that a peptide that stimulates angiogenesis and cell proliferation could affect existing tumors (reviews also report anti-cancer activity in vitro; unresolved) |
Interactions
| # | Interaction |
|---|---|
| 1 | No formal human interaction studies exist |
| 2 | Topical vitamin C and strong acids may destabilize the copper complex in a formulation (formulation issue, not a drug interaction) |
Contraindications
| # | Contraindication |
|---|---|
| 1 | Known copper metabolism disorder such as Wilson disease (theoretical, injected form) |
| 2 | Pregnancy and breastfeeding for the injectable (no data) |
| 3 | Competitive athletes should avoid the injectable pending clarification of WADA status |
How do people access GHK-Cu legally?
Typical cost: Topical cosmetic serums and creams roughly 20 to 100 USD per bottle. There is no lawful compounded price for injectable GHK-Cu: it is off 503A Category 2 but is not on the 503A bulks list and was not recommended by PCAC in July 2026. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity.
Verified access options
Step 1
Topical cosmetic products containing GHK-Cu are sold over the counter without a prescription, as long as they make only cosmetic claims.
Step 2
No lawful compounded path for injectable GHK-Cu today: FDA lists it as a withdrawn 503A nomination, so it is off Category 2 but not on the 503A bulks list, and a 503A pharmacy has no federal basis to compound it from bulk.
Step 3
Not available as an FDA approved drug; injectable products labeled research use only are not lawful for human use.
Access paths are verified against public regulatory records and prescriber licensing. We never list unlicensed vendors.
Compare GHK-Cu
What's actually offered, and what that means for you
Licensed compounding pharmacies, clinics, and telehealth prescribers openly offer many unapproved peptides, and prescribers write prescriptions for them. That does not make GHK-Cu lawful. GHK-Cu is not FDA approved and not on the 503A bulks list, so a pharmacy has no lawful basis to compound it. [4] [9]
Enforcement is uneven. FDA mostly acts through warning letters to compounders and online sellers, Category 2 safety listings, and import alerts that let it detain shipments, rather than stopping every pharmacy. State pharmacy boards oversee pharmacies day to day, and their rules differ. [9] [10] [11] [12] [13]
What changes for you
- No FDA review of the product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [13]
- Identity, purity, sterility, and dose accuracy can vary from batch to batch. [9]
- Insurance rarely covers it, so you usually pay cash.
- For tested athletes, WADA status is unclear; ask your anti-doping organization before any use. [6]
What to check
These checks lower some risks, but they do not make an unlawfully compounded product lawful or safe. Check for:
- A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [13]
- A real evaluation by a licensed prescriber, not just an online form.
- A certificate of analysis for the specific batch.
Blends that contain GHK-Cu
GHK-Cu is sold in premixed blends under the names below. No blend has been tested as a combination, and a mix is only as lawful as its least lawful ingredient.
Frequently asked questions
What does GHK-Cu do?
GHK-Cu is a small peptide from human plasma (the liquid part of blood) that binds copper and delivers it to cells. In cell and animal studies it draws repair cells to wounds, increases production of collagen, elastin, and glycosaminoglycans (the proteins and gel-like molecules that give skin its structure), and dampens inflammatory signals, and animal wounds heal faster with it. In people, the evidence is limited to skin products applied to the surface, where small cosmetic studies report firmer, more elastic skin and fewer fine lines. [1] [2] [3]
Are copper peptides the same as GHK-Cu?
Mostly, but not always. Copper peptide is a skin care label for ingredients that pair copper with a short peptide, and GHK-Cu (listed on labels as copper tripeptide-1) is the one the research is about. A product sold as copper peptides may contain GHK-Cu at an unstated strength or a different copper complex, and results from GHK-Cu studies apply only to GHK-Cu. [2] [3]
Topical vs injected GHK-Cu: what do studies cover?
Every human study is topical. Reviews summarize small cosmetic studies of creams and serums in aged or sun damaged skin, and one independent randomized trial after laser resurfacing found no objective improvement over skin care without GHK-Cu, only higher patient satisfaction. Injected GHK-Cu has animal data from systemic dosing but no human study of any kind, so its effects and safety in people are unknown. Topical products are lawful cosmetics; the injectable has no lawful compounded path. [1] [2] [4] [7]
What are the side effects of GHK-Cu, and is it safe?
Topical GHK-Cu is generally well tolerated in cosmetic studies, with occasional irritation. The injectable has no systematic human safety data; anecdotal reports mention injection site pain, and copper overload from repeated large injected doses is a theoretical concern. Reviews report both pro-repair and anti-cancer activity in cell studies, so the effect on existing tumors is unresolved. Unapproved injectable products also carry identity and purity risks. [1] [2] [8]
Is GHK-Cu FDA approved?
No. GHK-Cu is not an FDA approved drug and not a component of one. As a cosmetic ingredient in creams and serums it is lawfully sold without FDA approval as long as the products make only cosmetic claims. Injectable GHK-Cu is a withdrawn 503A nomination: it is off Category 2 but not on the 503A bulks list and was not reviewed by the advisory committee in July 2026, so a 503A pharmacy has no federal basis to compound it from bulk. Injectable vials sold as research chemicals are not lawful for human use. [4] [5]
Does GHK-Cu work for skin aging and wrinkles?
The topical evidence is encouraging but thin. Reviews describe controlled cosmetic studies in which GHK-Cu creams tightened loose skin, improved elasticity, firmness, and density, and reduced fine lines, wrinkles, and photodamage over 8 to 12 weeks. Those studies are small, industry associated, and cited through reviews written by the peptide's discoverer, and the one independent randomized trial identified found no objective benefit after laser resurfacing. PeptideAgent grades the evidence human-observational. [2] [3] [7]
Does GHK-Cu help hair growth?
Reviews report that GHK-Cu increases hair follicle size in animal and ex vivo models, which is the basis for copper peptide hair products. No indexed randomized human trial of GHK-Cu for hair loss was identified, so the human claim is unproven. [2] [3]
Is GHK-Cu banned by WADA?
It is not named on the WADA Prohibited List, and a topical cosmetic is not a doping concern. Injected GHK-Cu is a pharmacological substance with no approval by any health authority for therapeutic use, which is the definition WADA uses for section S0 (non-approved substances), so athletes should treat the injectable as prohibited and check with their anti-doping organization. [6]
Decisions about starting, stopping, or combining any treatment belong with a licensed clinician who knows your history.
From the blog
- Topical vs injectable GHK-Cu: what the evidence shows
Topical GHK-Cu has small skin studies and is a lawful cosmetic. Injectable GHK-Cu has no human trial and no lawful compounding path. Evidence, absorption, safety, and legality compared.
- Minoxidil side effects: topical, oral, shedding, and pets
Minoxidil side effects differ by form: scalp irritation and unwanted facial hair with topical use, body hair and fluid retention with oral use. Plus shedding, pregnancy, and the danger to cats.
- Oral minoxidil for hair loss: evidence and side effects
Low-dose oral minoxidil is an off-label hair loss treatment. What the FDA label for the blood pressure tablet says, what the hair loss trials found, and the side effects they reported.
- Copper peptides for hair: what the studies show
Does GHK-Cu help with hair growth? Copper peptides enlarge hair follicles in lab and mouse studies, but no randomized trial of GHK-Cu alone for hair loss exists. How they compare with minoxidil.
- Klow vs Glow peptide: what KPV adds and what is known
Klow is the Glow blend (GHK-Cu, BPC-157, TB-500) plus KPV. Each ingredient compared, what KPV is claimed to add, how both relate to the Wolverine stack, and why no study tests either blend.
- Peptide before and after: trial results vs marketing photos
Measured peptide before and after results: GLP-1 weight change, tesamorelin visceral fat, and regain after stopping, compared with Glow, GHK-Cu, BPC-157, and Wolverine claims.
More on the blog
Sources
Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.
- [1]Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci 2018PubMed 29986520, 2018
- [2]Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int 2015PubMed 26236730, 2015
- [3]Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed 2008PubMed 18644225, 2008
- [4]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
- [5]FDA: Is it a cosmetic, a drug, or both? (or is it soap?)FDA, 2024
- [6]WADA Prohibited List, section S0 non-approved substancesWADA, 2026
- [7]Miller TR et al. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg 2006PubMed 16847171, 2006
- [8]Mendias CL, Awan TM. Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Med 2026PubMed 41966639, 2026
- [9]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (Category 2)FDA
- [10]FDA: Compounding inspections, recalls, and other actions (warning letters to compounders)FDA
Cite this page
Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.
- APA style
PeptideAgent. (2026, September 23). GHK-Cu: evidence, legality, and access. https://peptideagent.ai/peptides/ghk-cu- HTML link
<a href="https://peptideagent.ai/peptides/ghk-cu">GHK-Cu: evidence, legality, and access</a>, PeptideAgent, updated September 23, 2026.